Bruxelles, Belgium; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Leuven, Belgium; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Dijon, France; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Nice, France; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Paris, France; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Saint Herblain, France; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Villejuif, France; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Padova, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Torino, Italy; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Den Haag, Netherlands; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Nijmegen, Netherlands; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Rotterdam, Netherlands; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme
Glasgow, United Kingdom; Research Site:
A Study of Tarceva (Erlotinib) in Patients With Recurrent Glioblastoma Multiforme